2. Search Result
Search Result
Results for "

necrotic

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dyes

1

Biochemical Assay Reagents

3

Peptides

1

Inhibitory Antibodies

4

Natural
Products

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14307
    Necrocide 1
    2 Publications Verification

    		 TRP Channel Eukaryotic Initiation Factor (eIF) Reactive Oxygen Species (ROS) Cancer
    Necrocide 1, a necrosis by sodium overload (NECSO) inducer, is a selective transient receptor potential melastatin 4 (TRPM4) agonist with an EC50 of 306.3 nM for human TRPM4. Necrocide 1 triggers TRPM4-dependent necrotic cell death through the induction of sodium influx. Necrocide 1 induces hallmarks of immunogenic cell death incurring calreticulin (CALR) exposure, ATP secretion and high mobility group box 1 (HMGB1) release. Necrocide 1 can be used for the study of breast and prostate cancer .
    Necrocide 1
  • HY-W018026
    Oxfenicine

    L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842

    		 Acyltransferase Apoptosis Cardiovascular Disease Metabolic Disease
    Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acids in the heart, protecting cardiac tissue from necrotic damage during ischemia, and also has an inhibitory effect on cardiac tissue apoptosis. In addition, Oxfenicine promotes lipolysis in a high-fat diet rat model. Oxfenicine can be used in the study of cardiovascular and metabolic diseases .
    Oxfenicine
  • HY-153468
    ErSO-TFPy

    TEQ103; Sera2

    		 Sodium Channel TRP Channel Cancer
    ErSO-TFPy (TEQ103) is an ERα+ tumor cell inhibitor with low nanomolar cytotoxic activity against ERα+ breast cancer cells. ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy dysregulates calcium homeostasis in ERα+ tumor cells, triggers the anticipatory unfolded protein response, and induces rapid immune cell-independent necrotic cell death. ErSO-TFPy can be used for the research of estrogen receptor alpha positive breast cancer .
    ErSO-TFPy
  • HY-D0917
    NIR-Red Dead Cell-1 Dye

    		DNA Stain Cancer
    NIR-Red Dead Cell-1 Dye is a DNA-binding fluorescent dye for non-living cells (Ex/Em=515 nm/531 nm). NIR-Red Dead Cell-1 Dye can intercalate into base pairs of double-stranded DNA and produce stronger fluorescence. NIR-Red Dead Cell-1 Dye is suitable for necrotic cells or late apoptotic cells with damaged cell membranes, showing green fluorescence under fluorescence microscopy or flow cytometry. NIR-Red Dead Cell-1 Dye can be used to distinguish live cells from dead cells and distinguish cell membrane integrity. NIR-Red Dead Cell-1 Dye can be attached to the surface of Feraheme (FH) nanoparticles (NPs) to obtain fluorescent dye-functionalized NPs for drug delivery studies .
    NIR-Red Dead Cell-1 Dye
  • HY-B1309
    Metacetamol

    AMAP

    		 Drug Derivative Mitochondrial Metabolism Infection Cancer
    Metacetamol (AMAP) is an analog of Acetaminophen (HY-66005). Metacetamol induces dose-dependent necrosis in primary hepatocytes via glutathione depletion, mitochondrial damage, and formation of mitochondrial protein adducts. Metacetamol derivatives act as anticancer and antibacterial agents. Metacetamol can be used in studies related to breast cancer, bacterial infections, and fungal infections (candidiasis) .
    Metacetamol
  • HY-D0918
    YO-PRO-1

    		Fluorescent Dye Others
    YO-PRO-1 is a non-cell-membrane-penetrating green fluorescent dye. YO-PRO-1 cannot penetrate normal cell membranes but can penetrate the membranes of apoptotic and necrotic cells. YO-PRO-1 has a high affinity for DNA. When it is not bound to DNA, it emits almost no fluorescence, and when it binds to DNA, it can emit green fluorescence (Ex/Em: 488/530±30 nM). YO-PRO-1 is often used together with Propidium Iodide (HY-D0815) to analyze and identify apoptotic and necrotic cells .
    YO-PRO-1
  • HY-145963
    DRB18
    1 Publications Verification

    		 GLUT Cancer
    DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity .
    DRB18
  • HY-15045
    INO-1001
    2 Publications Verification

    		 PARP Cancer
    INO-1001 is a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death . INO-1001 has anti-tumor effects .
    INO-1001
  • HY-151369
    AV123

    		RIP kinase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC50=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC50=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases .
    AV123
  • HY-135517
    RXP470.1

    RXP-470

    		 MMP Cardiovascular Disease
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .
    RXP470.1
  • HY-N6861
    Lucidenic acid B

    		Apoptosis Cancer
    Lucidenic acid B is a natural compound isolated from Ganoderma lucidum, induces apoptosis of cancer cells, and causes the activation of caspase-9 and caspase-3, and cleavage of PARP. Lucidenic acid B does not affect the cell cycle profile, or the number of necrotic cells .
    Lucidenic acid B
  • HY-149393
    RIPK3-IN-3

    		Mixed Lineage Kinase RIP kinase Cancer
    RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC50=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .
    RIPK3-IN-3
  • HY-76573
    ML-10

    		Apoptosis Cardiovascular Disease Cancer
    ML-10 is a small molecule apoptosis probe. Due to the presence of fluorine atoms, ML-10 can be radiolabeled with 18F isotopes and can be used for apoptosis positron emission tomography imaging studies. ML-10 is selectively taken up and accumulated in apoptotic cells, while being excluded from live or necrotic cells. In addition, the uptake of ML-10 is associated with apoptotic features such as caspase activation, Annexin-V binding, and disruption of mitochondrial membrane potential .
    ML-10
  • HY-131058
    Muscotoxin A

    		ADC Payload Cancer
    Muscotoxin A is an ADC cytotoxin. Muscotoxin A is a cytotoxic lipopeptide that permeabilizes mammalian cell membranes and induces necrotic cell death .
    Muscotoxin A
  • HY-178380
    HDAC8-IN-14

    		HDAC Reactive Oxygen Species (ROS) Apoptosis Necroptosis Biochemical Assay Reagents Caspase Bcl-2 Family Inflammation/Immunology Cancer
    HDAC8-IN-14, a curcuminoid derivative, is a selective HDAC8 inhibitor with a Ki of 9 nM. HDAC8-IN-14 induces the production of reactive oxygen species (ROS), disrupts mitochondrial membrane potential, and promotes apoptosis. HDAC8-IN-14 can significantly promote the accumulation of cells in the sub-G0/G1 phase, consistent with apoptotic or necrotic cell death. HDAC8-IN-14 induces upregulation of cytochrome c, cleaved caspase-3, and the pro-apoptotic protein Bak while leaving the anti-apoptotic Bcl-2 levels unaltered. HDAC8-IN-14 can be used for the study of leukemia .
    HDAC8-IN-14
  • HY-107940
    Sutilains

    		Proteolytic Enzyme Others
    Sutilains is a proteolytic enzyme that dissolves necrotic tissue and hyaluronidase. Sutilains can be used as a topical debriding agent in burns .
    Sutilains
  • HY-119599
    Linearolactone

    		Parasite Others
    Linearolactone is a compound with anti-Giardia activity that induces necrotic death of Giardia trophozoites and may act through a predicted target protein.
    Linearolactone
  • HY-148052
    RIPK3-IN-2

    		RIP kinase Cancer
    RIPK3-IN-2 is a RIP3 inhibitor. RIPK3-IN-2 can be used in diseases caused by or associate with activated necrotic pathways research .
    RIPK3-IN-2
  • HY-153436
    RIP1 kinase inhibitor 6

    		RIP kinase Cancer
    RIP1 kinase inhibitor 6 is a potent and selective RIP1 kinase inhibitor with an IC50 of < 100 nM in human R1P1 kinase assay. RIP1 kinase inhibitor 6 is extracted from patent WO2020103884, example 80 .
    RIP1 kinase inhibitor 6
  • HY-117142
    Quizalofop-P

    		Acetyl-CoA Carboxylase Others
    Quizalofop-P is absorbed through weed stems and leaves, conducts upward and downward in plants, accumulates at the top and intermediate meristems, inhibits cellular fatty acid synthesis, and makes weeds necrotic. Quizalofop-P is highly selective between grass weeds and dicotyledonous crops .
    Quizalofop-P
  • HY-130369
    NSC10010 hydrochloride

    		Bacterial Necroptosis HSV Infection Cancer
    NSC10010 hydrochloride inhibits gammaherpesvirus associated B-lymphomas growth through activation of NF-kB and c-Myc-mediated signaling pathways. NSC10010 hydrochloride induces necrotic cell death in gammaherpesvirus infected B-cells. NSC10010 hydrochloride is also an inhibitor of Mtb ClpC1 ATPase .
    NSC10010 hydrochloride
  • HY-176218
    TTTE

    		Drug Derivative Inflammation/Immunology
    TTTE is a sulfone bischalcone derivative. TTTE has major anti-necrotic, anti-inflammatory and anti-fibrotic activities. TTTE exerts regulatory effects by downregulating key molecules such as Caspase-3, TNF-α, NF-κB and TGF-β. TTTE can be used in the study of liver injury .
    TTTE
  • HY-155804
    RIP1 kinase inhibitor 8

    		Necroptosis RIP kinase Inflammation/Immunology
    RIP1 kinase inhibitor 8 (Compound 77) is a potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitor with an IC50 of 20 nM. RIP1 kinase inhibitor 8 prevents necrotic cell death. RIP1 kinase inhibitor 8 shows a favorable pharmacokinetic profile in multiple species .
    RIP1 kinase inhibitor 8
  • HY-15045A
    INO-1001 mesylate

    		PARP Cancer
    INO-1001 mesylate is a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor. INO-1001 mesylate is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death . INO-1001 mesylate has anti-tumor effects .
    INO-1001 mesylate
  • HY-117142R
    Quizalofop-P (Standard)

    		Acetyl-CoA Carboxylase Reference Standards Others
    Quizalofop-P (Standard) is the analytical standard of Quizalofop-P. This product is intended for research and analytical applications. Quizalofop-P is absorbed through weed stems and leaves, conducts upward and downward in plants, accumulates at the top and intermediate meristems, inhibits cellular fatty acid synthesis, and makes weeds necrotic. Quizalofop-P is highly selective between grass weeds and dicotyledonous crops .
    Quizalofop-P (Standard)
  • HY-P11182
    ChMAP-28

    		Bacterial Infection Cancer
    ChMAP-28 is an antimicrobial peptide. ChMAP-28 can be derived from goat Capra hircus. ChMAP-28 can initiate necrotic death. ChMAP-28 is effective in killing many bacteria, including strains resistant to Polymyxin and Meropenem (HY-13678). ChMAP-28 shows antitumor activity against acute promyelocytic leukemia, epidermoid carcinoma, melanoma, breast adenocarcinoma .
    ChMAP-28
  • HY-151624
    PARP-2-IN-2

    		PARP Apoptosis Cancer
    PARP-2-IN-2 (compound 27) is a PARP 2 inhibitor with an IC50 value of 0.057 μM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .
    PARP-2-IN-2
  • HY-165492
    Opc 14117

    		Reactive Oxygen Species (ROS) NF-κB Apoptosis Neurological Disease Inflammation/Immunology
    OPC-14117 is an orally active superoxide radical scavenger that can cross the blood-brain barrier. OPC-14117 inhibits the oxidative stress cascade reaction, significantly reducing the increase in tissue osmotic pressure and alleviating brain edema in the brain contusion model. OPC-14117 blocks the NF-κB-dependent apoptotic pathway in the striatum neuron apoptosis model induced by Quinolinic acid (HY-100807). OPC-14117 can reduce the necrotic volume, protect hippocampal CA3 neurons and restore cognitive function. OPC-14117 can be used to study secondary brain injury and improve neurological prognosis .
    Opc 14117
  • HY-170958
    Scr-IN-1

    		Src Apoptosis Cancer
    Scr-IN-1 (Compound 4e) is a Tyrosine kinase inhibitor. Scr-IN-1 inhibits HCT-116 cells and MIA-PaCa-2 cells with IC50s of 0.16 μM and 1.16 μM, respectively. Scr-IN-1 displays selectivity profile on HCT-116 cells and MIA-PaCa-2 cells with SI > 625 and SI > 86, respectively. Scr-IN-1 induces Apoptosis in HCT-116 colon cancer cell and does not cause any change in the rate of necrotic cells. Scr-IN-1 is a novel SRC kinase inhibitor candidate for HCT-116 cells. Scr-IN-1 is potential for cancer research .
    Scr-IN-1
  • HY-183232
    SRS6-11

    		Necroptosis Cancer
    SRS6-11 is an iron death-independent necrotic cell death (Necrosis) inducer. SRS6-11 retains significant lethality in the presence of α-tocopherol (HY-W020044). SRS6-11 can be used in fibrosarcoma research .
    SRS6-11
  • HY-P992094
    Capromab

    		PSMA Cancer
    Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer .
    Capromab
  • HY-P11638
    Mitochondrial-targeted peptide BP29

    		Mitochondrial Metabolism Neurological Disease Inflammation/Immunology
    Mitochondrial-targeted peptide BP29 is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 can be used for the research of Friedreich's ataxia .
    Mitochondrial-targeted peptide BP29
  • HY-183414
    C5aR antagonist-1

    		Complement System Endocrinology
    C5aR antagonist-1 is a potent C5aR antagonist with an IC50 of < 5 nM. C5aR antagonist-1 is applicable to the research of crescentic and necrotizing glomerular lesions .
    C5aR antagonist-1
  • HY-181146
    MK-7762

    TBD09

    		 Bacterial Infection
    MK-7762 is an orally active xazolidinone compound with antitubercular activity. MK-7762 inhibits MAO-B and mammalian mitochondrial protein synthesis. MK-7762 reduces lung bacterial burden in BALB/c mouse models of acute and chronic tuberculosis infection, penetrates caseous necrotic lung lesions in C3HeB/FeJ mice, and maintains concentrations above unbound MIC in lesion compartments. MK-7762 can be used for the research of tuberculosis .
    MK-7762
  • HY-P11638A
    Mitochondrial-targeted peptide BP29 acetate

    		Mitochondrial Metabolism Neurological Disease Inflammation/Immunology
    Mitochondrial-targeted peptide BP29 acetate is a mitochondria-targeted iron chelator linked to a mitochondria-homing SS-peptide. Mitochondrial-targeted peptide BP29 acetate protects human primary skin fibroblasts against ultraviolet A-induced oxidative damage to mitochondrial membranes, ATP depletion, and necrotic cell death. Mitochondrial-targeted peptide BP29 acetate prevents hydrogen peroxide-induced oxidative stress and cytotoxicity in both healthy and Friedreich's ataxia skin fibroblasts. Mitochondrial-targeted peptide BP29 acetate can be used for the research of Friedreich's ataxia .
    Mitochondrial-targeted peptide BP29 acetate
  • HY-179526
    Sino-C

    		Apoptosis PARP Cancer
    Sino-C is a Sinomenine (HY-15122) derivative with anticancer activity. Sino-C broadly disrupts cholesterol homeostasis by upregulating key genes such as SREBF2 and HMGCS1, leading to intracellular cholesterol accumulation and lipid droplet formation. Sino-C-induced metabolic dysregulation further triggers lipid peroxidation and endoplasmic reticulum (ER) stress, initiating a unique form of hybrid cell death including apoptotic (cleaved PARP) and necrotic-like features. Sino-C thus serves as a useful compound for research in colorectal cancer, lung cancer and breast cancer .
    Sino-C
  • HY-N14094
    Tubulosine

    		JAK Apoptosis Autophagy Cancer
    Tubulosine is an alkaloid. Tubulosine can be isolated from Pogonopus tubulosus (DC.) Schumann. Tubulosine is an ATP-competitive, selective JAK3 inhibitor with an IC50 value of 9.9 nM. Tubulosine also inhibits the kinase activities of other JAK family members, the extent of inhibition is less than that of JAK3, with IC50 values of 69.5, 84.9 and 76.3 nM for JAK1, JAK2 and TYK2, respectively. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3. Tubulosine induces apoptotic and necrotic/autophagic cell death. Tubulosine inhibits the process of peptide chain elongation by eukaryotic polysomes by, specifically preventing the elongation-factor-2-dependent step of translocation. Tubulosine exhibits anticancer activity in breast cancer cells .
    Tubulosine
  • HY-181528
    JAK1/CDK7-IN-1

    		JAK CDK Cancer
    JAK1/CDK7-IN-1 (compound 11) is a JAK1/CDK7 inhibitor and cytotoxic agent.JAK1/CDK7-IN-1 forms a stable, tightly bound complex with JAK1.JAK1/CDK7-IN-1 disrupts cell cycle, induces G2/M phase arrest, and increases Pre-G1 phase cell proportion.JAK1/CDK7-IN-1 induces apoptosis, elevates caspase 1, 3, and 9 levels, and triggers apoptotic and necrotic cell death.JAK1/CDK7-IN-1 can be used for the research of breast cancer, prostate cancer .
    JAK1/CDK7-IN-1
  • HY-B0356G
    Ciprofloxacin

    Bay-09867

    		 Bacterial Topoisomerase Akt β-catenin Inflammation/Immunology
    Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity .
    Ciprofloxacin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: